Biothera Pharmaceuticals to Present at the Canaccord Genuity Growth Conference

EAGAN, MN — August 3, 2016 — Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 11:30 a.m. Eastern Time in Boston, Mass. Mr. Labinger will provide an overview of Biothera Pharmaceuticals and a business update.

About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in trials in over 400 subjects and has established proof of concept in multiple clinical studies, including single-arm and randomized phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer, and chronic lymphocytic leukemia. The Company is currently planning phase 2 clinical trials to evaluate Imprime PGG in combination with checkpoint inhibitors in NSCLC, triple negative breast cancer, melanoma and squamous cell carcinoma of the head and neck.

Contact:
David Walsh
SVP Communications
Biothera Pharmaceuticals, Inc.
651-256-4606
dwalsh@biothera.com

 

Share

David Walsh

Leave a Reply

Your email address will not be published. Required fields are marked *